Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Erleada is a prescription androgen receptor inhibitor containing apalutamide. It is used for metastatic castration-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer. Tablets come in 60 mg and 240 mg strengths and are taken once daily with or without food.
read more about erleada ...Apalutamide binds directly to the ligand-binding domain of the androgen receptor. It reduces androgen binding, movement of the receptor into the cell nucleus, and androgen receptor interaction with DNA. These actions reduce androgen receptor signaling that contributes to prostate cancer cell growth.
Erleada treats metastatic castration-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer. Patients also receive a gonadotropin-releasing hormone analog unless they have had bilateral orchiectomy. Current labeling does not establish safety or efficacy in children or females.
The recommended dose is 240 mg by mouth once daily. Tablets are swallowed whole and are not crushed or split. Patients with severe hepatic impairment use 120 mg once daily under the June 2026 label. Dose interruption or reduction is used for selected serious or intolerable adverse reactions.
Serious concerns include cerebrovascular and ischemic cardiovascular events, fractures, falls, seizures, severe skin reactions, interstitial lung disease or pneumonitis, and fetal harm. Erleada can also interfere with certain digoxin immunoassays and has substantial interaction potential with medicines metabolized by several CYP enzymes and transport proteins.
Erleada treats metastatic castration-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer.
The standard dose is 240 mg once daily with or without food.
Current labeling recommends 120 mg once daily for severe hepatic impairment.
Yes. Seizures have occurred during treatment, and seizure risk is addressed in current prescribing information.
Apalutamide. MedlinePlus. https://medlineplus.gov/druginfo/meds/a618018.html. Date Accessed September 30, 2026.
Apalutamide. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/apalutamide. Date Accessed September 30, 2026.
Apalutamide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/24872560. Date Accessed September 30, 2026.
DailyMed - ERLEADA (apalutamide) tablet, film coated. https://www.dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5. Date Accessed September 30, 2026.
ERLEADA (apalutamide) Prescribing Information. Johnson & Johnson. https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/ERLEADA-pi.pdf. Date Accessed September 30, 2026.